Cytek Biosciences, Inc.

NASDAQ:CTKB

Medical - Devices

Healthcare
$5.92 -2.64%

-$0.11 today

Market cap
$774.24M
Beta
1.19
P/E (TTM)
-6.7
EPS (TTM)
-$0.57
52W Low $2.90High $6.18

Volume 1.05M

Average 0.88M

CTKB Deferred Income Tax

The difference between tax expense recognized and tax actually paid in cash during the period.

Cytek Biosciences, Inc.NASDAQ: CTKB

Deferred Income Tax · Q1 FY2026 · quarter ended Mar 2026

Deferred income tax dips below year-ago levels

Q1 FY2026 deferred income tax of $183K (cash outflow) fell 45.5% year over year, behind the +10132.7% change in trailing-twelve-month deferred income tax.

Context

  • Deferred income tax amounted to 16.7% of revenue in FY2025, up 15.2 pp from a year earlier.
  • Deferred income tax increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -45.5% toward the trailing-twelve-month pace of +10132.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$183K-100.5% QoQ
Last fiscal yearDec 2025
$33.56M+1262.8% YoY
LTMMar 2026
$33.71M+10132.7% YoY
Deferred Income Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-45.5%——
1 year+1262.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Income Tax history

USD · from the cash flow

Latest · FY2025
33.56M USD
Year-over-year change
+1262.8%

Deferred Income Tax vs competitors

How CTKB compares with its peers on the latest reported figures

  • CTKB's LTM Mar 2026 deferred income tax of $33.71M is the 2nd largest of the 6 companies compared; the peer median is $1.43M.
  • Its year-over-year change of +10132.7% is the highest of 3, against a peer median of -29.6%.
  • Deferred income tax amounts to 16.5% of revenue for CTKB, versus a peer median of 0.2%.
CTKB Competitors Peer median
Deferred Income Tax for CTKB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BRKRBruker CorporationLTM Jun 2026$97M +21.1%+91.8%2.8%
CTKBCytek Biosciences, Inc.LTM Mar 2026$33.71M +10132.7%—16.5%
AAgilent Technologies, Inc.LTM Jul 2026$18M -80.2%—0.2%
TXG10x Genomics, Inc.LTM Jun 2026$1.43M ——0.2%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$0 ——0.0%
LABStandard BioTools Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding CTKB) $1.43M-29.6%+91.8%0.2%

Competitors are the stored peer set for CTKB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income3.03M2.48M(12.15M)(6.02M)(66.54M)
Depreciation & Amortization1.24M5.66M9.23M10.49M11.98M
Deferred Income Tax000(2.89M)33.56M
Stock-Based Compensation6.59M16.6M22.05M26.85M24.59M
Change in Working Capital(8.65M)(39.93M)(10.51M)7.71M(4.79M)
Accounts Receivables(12.37M)(19.74M)(7.33M)(5.43M)368K
Inventory(7.07M)(17.65M)4.29M14.76M(5.24M)
Accounts Payables(256K)1.86M(1.78M)2.58M448K
Other Working Capital11.05M(4.39M)(5.68M)(4.2M)(366K)
Other Non-Cash Items2.42M2.96M(3.34M)(10.77M)(3.47M)
Operating Cash Flow4.63M(12.23M)5.28M25.38M(4.69M)
Capital Expenditures(4.36M)(9.87M)(4.83M)(3.53M)(4.08M)
Acquisitions (Net)(16.63M)0(45.13M)(471K)252K
Purchases of Investments0(46.04M)(175.94M)(274.06M)(278.16M)
Sales of Investments00132M195M292.21M
Other Investing Activities0(120K)(179K)84K(107K)
Investing Cash Flow(20.99M)(55.91M)(93.89M)(82.97M)10.12M
Debt Repayment(2.77M)2.93M(565K)3.62M837K
Common Stock Issued215.69M2.79M001.47M
Common Stock Repurchased00(44.15M)(21.61M)(15.07M)
Dividends Paid00000
Other Financing Activities642K(209K)2.9M2.17M(669K)
Financing Cash Flow213.56M5.51M(41.81M)(15.82M)(13.43M)
Effect of Forex Changes1.3M(2.49M)(1.45M)4.53M109K
Net Change in Cash198.5M(65.12M)(131.87M)(68.89M)(7.89M)
Free Cash Flow266K(22.1M)454K21.85M(8.77M)

Cytek Biosciences, Inc.

NASDAQ:CTKB

Intrinsic Alpha fair value

Locked

Current Price

$5.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.